Avenacy Announces Launch of Dexmedetomidine Injection, USP in the U.S. Market

Represents the Company’s fourteenth product launch since inception in October 2023

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Dexmedetomidine Injection, USP in the United States as a therapeutic generic equivalent for Precedex® as approved by the U.S. Food and Drug Administration. Dexmedetomidine Injection, USP is an alpha2-adrenergic receptor agonist indicated for:

• Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Dexmedetomidine Injection should be administered by continuous infusion not to exceed 24 hours.
• Sedation of non-intubated adult patients prior to and/or during surgical and other procedures.

Avenacy's Dexmedetomidine Injection, USP is available as 200 mcg (base) per 2 mL (100 mcg (base) per mL) single-dose vials, with 25 vials per carton. In line with Avenacy’s mission to champion patient safety and streamline patient care, Dexmedetomidine Injection, USP will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection.

Avenacy will begin shipping Dexmedetomidine Injection, USP to wholesale partners this week. The Company is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP-standards.

Dexmedetomidine Injection, USP had U.S. sales of approximately $19 million for the twelve months ending in September 2024.¹

Please see link for Full Prescribing Information.

PRECEDEX® is a registered trademark of Orion Corporation.

¹Source: IQVIA

About Avenacy

Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications.

Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit http://www.avenacy.com/.